| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/138161212802002788 |
| P698 | PubMed publication ID | 22591426 |
| P50 | author | Judith R Kroep | Q56920064 |
| P2093 | author name string | Kroep JR | |
| P433 | issue | 25 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 3735-3740 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Current Pharmaceutical Design | Q5195068 |
| P1476 | title | Advances in epithelial ovarian cancer therapy | |
| P478 | volume | 18 |
| Q35635298 | Identification of epithelial ovarian tumor-specific aptamers |
| Q38969949 | Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. |
| Q40462951 | PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis. |
| Q34721579 | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells. |
Search more.